January 2026
1. KELSHIKER MA, Bachtiger P, Petri CF, Nakhare S, et al
   Triple cardiovascular disease detection with an artificial intelligence-enabled stethoscope (TRICORDER) in the UK: a cluster-randomised controlled implementation trial.
   Lancet. 2026 Jan 28:S0140-6736(25)02156-7. doi: 10.1016/S0140-6736(25)02156.
   

   >> Share

   
   
2. MENSAH GA, Prabhakaran D, Mbakwem AC, Narula J, et al
   Closing the prevention gap in heart failure: World Heart Federation.
   Lancet. 2026;407:221-222.
   

   >> Share

   
   November 2025
3. CANNATA A, Crespo-Leiro MG, Bromage DI, Ruschitzka F, et al
   Heart failure with reduced ejection fraction.
   Lancet. 2025 Nov 27:S0140-6736(25)01851-3. doi: 10.1016/S0140-6736(25)01851.
   

   >> Share

   
   
4. SLIWA K, Hilfiker-Kleiner D, Damasceno A, Al Farhan H, et al
   Peripartum cardiomyopathy.
   Lancet. 2025;406:2483-2493.
   

   >> Share

   
   August 2025
5. KOHSAKA S, Heidenreich PA
   Vericiguat across the heart failure spectrum.
   Lancet. 2025 Aug 29:S0140-6736(25)01765-9. doi: 10.1016/S0140-6736(25)01765.
   

   >> Share

   
   
6. BUTLER J, McMullan CJ, Anstrom KJ, Barash I, et al
   Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial.
   Lancet. 2025 Aug 29:S0140-6736(25)01665-4. doi: 10.1016/S0140-6736(25)01665.
   

   >> Share

   
   
7. ZANNAD F, O'Connor CM, Butler J, McMullan CJ, et al
   Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials.
   Lancet. 2025 Aug 29:S0140-6736(25)01682-4. doi: 10.1016/S0140-6736(25)01682.
   

   >> Share

   
   
8. ROSSELLO X, Prescott EIB, Kristensen AMD, Latini R, et al
   beta blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trials.
   Lancet. 2025 Aug 29:S0140-6736(25)01592-2. doi: 10.1016/S0140-6736(25)01592.
   

   >> Share

   
   
9. ANDERSON CS, Hua C, Wang Z, Wang C, et al
   Influenza vaccination to improve outcomes for patients with acute heart failure (PANDA II): a multiregional, seasonal, hospital-based, cluster-randomised, controlled trial in China.
   Lancet. 2025 Aug 28:S0140-6736(25)01485-0. doi: 10.1016/S0140-6736(25)01485.
   

   >> Share

   
   
10. BHATT AS, Vardeny O
    Influenza vaccination in heart failure: a shot worth taking?
    Lancet. 2025 Aug 28:S0140-6736(25)01679-4. doi: 10.1016/S0140-6736(25)01679.
    

    >> Share

    
    
11. THE LANCET
    Heart failure: time to prioritise prevention.
    Lancet. 2025 Aug 28:S0140-6736(25)01775-1. doi: 10.1016/S0140-6736(25)01775.
    

    >> Share

    
    
12. KHAN SS, Berwanger O, Fiuzat M, McMurray JJ, et al
    Prioritising the primary prevention of heart failure.
    Lancet. 2025 Aug 28:S0140-6736(25)01393-5. doi: 10.1016/S0140-6736(25)01393.
    

    >> Share

    
    
13. UDELL JA, Bahit MC, Campbell P, Butler J, et al
    Prevention of heart failure after acute myocardial infarction.
    Lancet. 2025 Aug 28:S0140-6736(25)01394-7. doi: 10.1016/S0140-6736(25)01394.
    

    >> Share

    
    
14. OSTROMINSKI JW, Cheng AYY, Nelson AJ, Neuen BL, et al
    Cardiovascular, kidney, and metabolic health: an actionable vision for heart failure prevention.
    Lancet. 2025 Aug 28:S0140-6736(25)01384-4. doi: 10.1016/S0140-6736(25)01384.
    

    >> Share

    
    
15. WALSH M, Collister D, Gallagher M, Mark PB, et al
    Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial.
    Lancet. 2025;406:695-704.
    

    >> Share

    
    February 2025
16. DEANFIELD J
    Effects of semaglutide on heart failure outcomes - Author's reply.
    Lancet. 2025;405:543-544.
    

    >> Share

    
    
17. HAN J, Shan D
    Effects of semaglutide on heart failure outcomes.
    Lancet. 2025;405:542.
    

    >> Share

    
    
18. NEVES JS, Packer M, Ferreira JP
    Effects of semaglutide on heart failure outcomes.
    Lancet. 2025;405:542-543.
    

    >> Share

    
    August 2024
19. RUTTEN FH, Groenewegen A
    Mineralocorticoid receptor antagonists for every patient with heart failure.
    Lancet. 2024 Aug 30:S0140-6736(24)01755-0. doi: 10.1016/S0140-6736(24)01755.
    

    >> Share

    
    
20. JHUND PS, Talebi A, Henderson AD, Claggett BL, et al
    Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis.
    Lancet. 2024 Aug 30:S0140-6736(24)01733-1. doi: 10.1016/S0140-6736(24)01733.
    

    >> Share

    
    
21. HAGE C
    GLP-1 receptor agonists in heart failure: how far to expand use?
    Lancet. 2024 Aug 29:S0140-6736(24)01763-X. doi: 10.1016/S0140-6736(24)01763.
    

    >> Share

    
    
22. KOSIBOROD MN, Deanfield J, Pratley R, Borlaug BA, et al
    Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.
    Lancet. 2024 Aug 29:S0140-6736(24)01643-X. doi: 10.1016/S0140-6736(24)01643.
    

    >> Share

    
    
23. DEANFIELD J, Verma S, Scirica BM, Kahn SE, et al
    Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.
    Lancet. 2024;404:773-786.
    

    >> Share

    
    
24. VADUGANATHAN M
    GLP-1 receptor agonists in heart failure.
    Lancet. 2024;404:727-729.
    

    >> Share

    
    April 2024
25. BUTLER J, Shah SJ, Petrie MC, Borlaug BA, et al
    Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.
    Lancet. 2024 Apr 4:S0140-6736(24)00469-0. doi: 10.1016/S0140-6736(24)00469.
    

    >> Share

    
    
26. DONAL E, L'Official G, Istratoaie S
    Semaglutide-a new treatment for obesity-related heart failure with preserved ejection fraction?
    Lancet. 2024 Apr 4:S0140-6736(24)00653-6. doi: 10.1016/S0140-6736(24)00653.
    

    >> Share

    
    March 2024
27. KIKOINE J, Kilani N, Pitta-Gros B, Yerly P, et al
    Remote haemodynamic monitoring in patients with heart failure.
    Lancet. 2024;403:808.
    

    >> Share

    
    
28. BRUGTS JJ, Aydin D, Clephas PRD, de Boer RA, et al
    Remote haemodynamic monitoring in patients with heart failure - Authors' reply.
    Lancet. 2024;403:808-809.
    

    >> Share

    
    
29. KOMAMURA K, Iwase M
    Remote haemodynamic monitoring in patients with heart failure.
    Lancet. 2024;403:807-808.
    

    >> Share

    
    February 2024
30. CAMPBELL P, Rutten FH, Lee MM, Hawkins NM, et al
    Heart failure with preserved ejection fraction: everything the clinician needs to know.
    Lancet. 2024 Feb 14:S0140-6736(23)02756-3. doi: 10.1016/S0140-6736(23)02756.
    

    >> Share

    
    November 2023
31. KHAN Y, Verhaeghe N, Devleesschauwer B, Cavillot L, et al
    Impact of the COVID-19 pandemic on delayed care of cardiovascular diseases in Europe: a systematic review.
    Lancet. 2023;402 Suppl 1:S61.
    

    >> Share

    
    August 2023
32. WILKOFF BL, Filippatos G, Leclercq C, Gold MR, et al
    Adaptive versus conventional cardiac resynchronisation therapy in patients with heart failure (AdaptResponse): a global, prospective, randomised controlled trial.
    Lancet. 2023 Aug 24:S0140-6736(23)00912-1. doi: 10.1016/S0140-6736(23)00912.
    

    >> Share

    
    May 2023
33. ANGERMANN CE
    Remote pulmonary artery pressure monitoring in heart failure care: part of the new normal?
    Lancet. 2023 May 19:S0140-6736(23)01010-3. doi: 10.1016/S0140-6736(23)01010.
    

    >> Share

    
    
34. BRUGTS JJ, Radhoe SP, Clephas PRD, Aydin D, et al
    Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial.
    Lancet. 2023 May 19:S0140-6736(23)00923-6. doi: 10.1016/S0140-6736(23)00923.
    

    >> Share

    
    April 2023
35. SCHLAICH MP, Bellet M, Weber MA, Bakris GL, et al
    Fluid retention and heart failure in the PRECISION trial - Authors' reply.
    Lancet. 2023;401:1335-1336.
    

    >> Share

    
    
36. KOHAN DE, Heerspink HJL
    Fluid retention and heart failure in the PRECISION trial.
    Lancet. 2023;401:1335.
    

    >> Share

    
    March 2023
37. HE J, Ouyang N, Guo X, Sun G, et al
    Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial.
    Lancet. 2023 Mar 2:S0140-6736(22)02603-4. doi: 10.1016/S0140-6736(22)02603.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share